{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "d5fd4632",
   "metadata": {},
   "source": [
    "### Mini Case 04: Momentum Machines - Fueling the Next Robotics Revolution\n",
    "\n",
    "**Case Background:**\n",
    "\n",
    "Momentum Machines (MM) is a privately held, innovative robotics company that started five years ago. Founded by Dr. Aris Thorne, a robotics visionary whose continued leadership and innovation are seen as critical to MM's ongoing success, and two PhD students, MM has developed groundbreaking AI-powered robotic arms for advanced manufacturing and logistics. Their technology significantly improves efficiency and precision, and they've secured several pilot programs with major manufacturers. A key element of their next-generation R&D, crucial for maintaining their competitive edge and for which a significant portion of the new $50M capital is earmarked, involves integrating a highly specialized, custom-fabricated optical sensor. This sensor is currently available from only a single, highly specialized supplier located in Switzerland, and all contracts with this supplier are denominated in Swiss Francs (CHF). A significant disruption to this supplier (due to operational issues, natural disasters, or other unforeseen events) could halt MM's next-gen R&D and delay critical product rollouts by at least a year, potentially leading to lost market opportunity and contractual penalties estimated to have a present value impact of $20 million (pre-tax). Furthermore, MM faces exchange rate risk on its payments for these critical sensors, as the USD/CHF rate can fluctuate significantly. The robotics-AI industry is also characterized by rapid technological obsolescence, intense competition from both established players and new entrants, and evolving regulatory considerations regarding automation and data.\n",
    "\n",
    "MM was initially funded by the founders and a small round from angel investors, $2 million for 20% equity which valued the company at $10 million post-money three years ago. Two years ago, they raised a Series A round of $10 million from \"Innovate Ventures,\" a VC firm, for 25% equity.\n",
    "\n",
    "Innovate Ventures, like many venture capital investors in early-stage companies, received convertible preferred stock. This type of stock typically gives the VC firm certain rights over common stockholders, such as a liquidation preference (e.g., a \"1x liquidation preference\") and the option to convert their preferred shares into common stock, usually when advantageous (e.g., at an IPO). These terms protect the VC's investment while allowing them to share in the upside.\n",
    "\n",
    "Dr. Thorne and the co-founders still hold a majority of the common stock. The company is now at a critical juncture. Their technology is proven, and demand is surging. To scale up production, expand their salesforce, and invest in next-generation R&D, CFO Lena Petrova estimates they need to raise $50 million in new capital.\n",
    "\n",
    "**Current Financial & Market Indicators (Estimates):**\n",
    "\n",
    "*   Projected Free Cash Flow to Firm (FCFF) for next year ($FCFF_1$) (after-tax): $8 million. This $FCFF_1$ is expected to grow at 15% per year for the following four years (Years 2-5), and then at a stable 3% per year indefinitely thereafter.\n",
    "*   Comparable publicly traded robotics/automation companies have an average unlevered beta ($\\beta_U$) of around 1.2.\n",
    "*   Current Risk-Free Rate ($r_f$): 3%\n",
    "*   Market Risk Premium ($MRP$): 7%\n",
    "*   Corporate Tax Rate ($\\tau_C$): 25%\n",
    "*   The company has minimal debt currently (mostly short-term operating lines).\n",
    "\n",
    "**The Board Meeting - Financing the Future:**\n",
    "\n",
    "The board of Momentum Machines, which includes Dr. Thorne, representatives from Innovate Ventures, and an independent director, is meeting to decide on the $50 million financing strategy. Several options are on the table:\n",
    "\n",
    "1.  **New Equity Round (Series B VC or Strategic Corporate Investment):** Lena Petrova has had initial discussions with larger VC firms, growth equity funds, and a major global manufacturing conglomerate. Any of these would involve significant equity, potentially with more complex preferred terms or strategic conditions (e.g., the conglomerate might offer $50 million for 20% common equity but also request exclusive technology access rights).\n",
    "    *   *Context Note: Convertible Preferred & Strategic Terms:* Innovate Ventures' Series A has a 1x non-participating liquidation preference; if MM were sold for $100M, Innovate Ventures would choose between getting their $10M back OR converting their 25% stake to get $25M. With \"participating preferred\" stock, often sought in later rounds or by certain VCs, they might get their $10M back *and* also share (participate) in the remaining proceeds alongside common shareholders. For instance, with 1x participating preferred on their $10M investment for 25%, in a $100M sale, they could potentially receive $10M (return of principal) + 25% of ($100M - $10M remaining) = $10M + $22.5M = $32.5M total, significantly more than their non-participating outcome. This illustrates why founders often resist participating preferred due to its higher potential payout to VCs and greater dilution to common shareholders. Strategic corporate investors, while also taking equity, often have different motivations than pure financial VCs; their \"Strategic Terms\" might add operational conditions such as technology access or market exclusivity, which can have non-obvious valuation and operational impacts beyond the headline equity percentage.\n",
    "\n",
    "2.  **Debt Financing (e.g., Venture Debt or Term Loan):** This option involves borrowing from specialized lenders or banks. For a company like MM, this would likely be venture debt, which is less dilutive to equity upfront than a new equity round. However, it introduces fixed repayment obligations, potentially straining cash flow for a growth-focused company. Lenders would also scrutinize MM's risk profile and ability to service debt.\n",
    "    *   *Context Note: Venture Debt Terms & \"Equity Kicker\":* Typically, venture debt for a company at MM's stage might carry an interest rate in the 8-12% range. To compensate for higher risk, venture debt providers often receive \"warrant coverage\" â€“ the right to buy a small percentage of company equity at a predetermined price, allowing them to share in the upside. Covenants may also be restrictive. (Accessing the public high-yield bond market at this stage is considered highly unlikely for a five-year-old private company like MM due to its lack of an established public credit rating. Were it possible, such bonds would likely be speculative-grade, demanding very high interest rates and significant collateral, making venture debt a more tailored option for companies at MM's growth stage).\n",
    "\n",
    "3.  **Initial Public Offering (IPO):** This represents the most transformative path, involving selling shares to the public for the first time. An IPO would provide substantial capital, offer liquidity to existing shareholders, and raise MM's public profile. However, it's complex, costly, involves stringent regulatory compliance, ongoing public reporting, and increased scrutiny.\n",
    "    *   *Context Note: IPO Underpricing:* Tech IPOs often see their stock price increase significantly on the first day of trading above the initial offer price. While this generates excitement, it means the company potentially raises less capital than it could have if priced higher, often seen as a way to compensate initial investors for risk.\n",
    "\n",
    "**Key Concerns & Questions Voiced:**\n",
    "\n",
    "*   Dr. Aris Thorne (Founder/CEO): \"My primary concern is maintaining control over our technological vision and company culture. I'm also keen to ensure our early employees and angel investors are eventually rewarded. How will these options impact my stake and the potential for future wealth creation for the original team?\"\n",
    "\n",
    "*   Innovate Ventures Rep: \"We need to maximize our return within a 3-5 year horizon for our fund. What path offers the clearest route to a profitable exit for us, and how does each financing option affect the company's valuation trajectory towards that exit?\"\n",
    "\n",
    "*   Lena Petrova (CFO): \"We need to consider the cost of capital associated with each option, the impact on our financial flexibility, and the signals we send to the market. What are the true costs and risks of each path beyond just the headline interest rate or equity percentage given up? And this single-supplier dependency for our new optical sensor from Switzerland is a major concern for the next-gen R&D. Beyond the supply disruption risk, if the Swiss Franc strengthens considerably against the US Dollar, our sensor costs could escalate significantly, impacting our project budgets and margins. If a supply disruption occurs, the $20 million impact could be devastating, especially if we've just taken on significant debt. Should we be actively seeking specialized supply chain disruption insurance for this, and also explore hedging our CHF currency exposure? How does the cost and availability of such insurance and hedging instruments, or the decision to self-insure these risks, interact with our choice of financing for the $50 million?\"\n",
    "\n",
    "*   Independent Director: \"How do these financing choices align with MM's long-term strategic goals? Are we building a company for a quick sale, or for sustained leadership? We also need to consider the implications for our overall capital structure and risk profile.\"\n",
    "\n",
    "**Discussion Points for Class:**\n",
    "\n",
    "1.  Cost of Capital & Risk:\n",
    "    \n",
    "    a.  Estimate Momentum Machines' unlevered cost of capital ($r_U$) based on the comparables.\n",
    "    \n",
    "    b.  How would each of the proposed financing options (New Equity Round, Debt Financing, IPO) likely affect MM's cost of equity ($r_E$), cost of debt ($r_D$), and WACC? Discuss qualitatively.\n",
    "\n",
    "2.  Valuation Implications:\n",
    "    \n",
    "    a.  Using the provided FCFF information and growth rates (15% for Y2-5, then 3% stable), what is a rough estimate of MM's current unlevered enterprise value ($V^U$) before the new $50M investment? How does this inform the pre-money valuation discussions for the new $50M round?\n",
    "    \n",
    "    b.  Considering the potential for complex \"Convertible Preferred & Strategic Terms\" in an equity round, how might these affect the true value proposition for MM and its existing shareholders compared to a simpler investment structure?\n",
    "\n",
    "3.  Capital Structure Theories in Play:\n",
    "    \n",
    "    a.  How does the Trade-Off Theory help analyze the \"Debt Financing\" option? What are the potential benefits and costs for a growth-stage tech company like MM?\n",
    "    \n",
    "    b.  How does the Pecking Order Theory relate to MM's situation, especially if Dr. Thorne has private information about the true potential of their next-gen R&D? Which financing option would this theory favor?\n",
    "    \n",
    "    c.  What signals would each financing choice (especially a large equity round vs. significant debt vs. IPO) send to the market about MM's prospects and management's confidence?\n",
    "\n",
    "4.  Control & Exit Considerations:\n",
    "    \n",
    "    a.  Discuss Dr. Thorne's concerns about control. Which financing options and potential terms (like those mentioned in the \"New Equity Round\" option, including participating preferred) pose the greatest threat to founder control and technological autonomy?\n",
    "    \n",
    "    b.  From Innovate Ventures' perspective, the Series A investor, which financing route for the $50M might be most attractive for facilitating their eventual exit? Consider the IPO underpricing note.\n",
    "\n",
    "5.  Beyond the Numbers (Strategic Fit):\n",
    "    \n",
    "    a.  If you were on the board, which financing option(s) would you lean towards for Momentum Machines at this stage, and why? What non-quantifiable factors would heavily influence your decision?\n",
    "    \n",
    "    b.  What are the key pieces of additional information Lena Petrova should gather before the board makes a final decision?\n",
    "\n",
    "6.  MM Propositions:\n",
    "    \n",
    "    a.  In a hypothetical world of perfect capital markets, how would MM Proposition I apply to MM's decision to raise $50 million via debt versus equity?\n",
    "    \n",
    "    b.  How does the introduction of corporate taxes ($\\tau_C = 25\\%$) change this perspective regarding the choice between debt and equity for MM?\n",
    "\n",
    "7.  Strategic Risk Management & Financing Interplay for Critical Components:\n",
    "    \n",
    "    a.  Consider the $20 million (pre-tax) potential loss from the optical sensor supply chain disruption. If the annual probability of this disruption is estimated at 5\\% and the beta of this specific loss ($B_L$) is assessed to be -0.1 (this negative beta reflects that such a disruption might be more financially damaging to MM if it coincides with a broader economic downturn when its other cash flows are also stressed), what would be an actuarially fair premium for MM to pay for insuring this specific risk for one year? (Use $r_f = 3\\%$ and $MRP = 7\\%$).\n",
    "    \n",
    "    b.  The optical sensors are priced in Swiss Francs (CHF). Suppose MM anticipates needing to pay CHF 5 million for sensors over the next year.\n",
    "    * Describe two methods MM could use to hedge against the risk of the CHF appreciating against the USD.\n",
    "    * If the current spot rate is 0.90 USD/CHF, the one-year forward rate is 0.91 USD/CHF, the current one-year US interest rate is 3.5%, and the current one-year Swiss interest rate is 1.0%, is covered interest parity holding? (Recall that CIP implies $F = S \\times (1+r_{USD})/(1+r_{CHF})$ or an equivalent formulation). If not, how could an arbitrageur profit? (Assume no transaction costs for simplicity).\n",
    "    \n",
    "    c.  Qualitatively, how might Momentum Machines' decision to purchase (or not purchase) specialized supply chain disruption insurance for the optical sensor, *and* its decision to hedge (or not hedge) its CHF currency exposure, be influenced by its chosen method of financing the $50 million capital need (e.g., a New Equity Round vs. Debt Financing)? Consider both the ability to pay premiums/hedging costs and the risk appetite of different capital providers.\n",
    "    \n",
    "    d.  Beyond insurance and financial hedges, what other non-financial risk mitigation strategies might Momentum Machines consider to address this critical optical sensor supply chain risk (both disruption and currency aspects)? Evaluate the feasibility of these alternatives for a company at MM's stage.\n",
    "    \n",
    "    e.  How does the concept of \"debt capacity\" relate to a firm's decision to insure (or not insure) significant, specific operational risks like this sensor supply disruption and hedge currency exposures? Could managing these risks effectively potentially *increase* MM's ability to take on debt?\n",
    "\n",
    "---"
   ]
  }
 ],
 "metadata": {
  "language_info": {
   "name": "python"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
